Novartis Ag (NVSEF) Revenue (2009 - 2025)

Novartis Ag has disclosed Revenue across 15 years of filings, most recently posting $14.1 billion for Q2 2025.

• Revenue for Q2 2025 came in at $14.1 billion, up 12.32% year-over-year; the trailing twelve-month figure through Jun 2025 was $73.1 billion (up 57.27% YoY), and the FY2025 annual result was $54.5 billion, up 8.38% from the prior year.
• Revenue came in at $14.1 billion for Q2 2025 at Novartis Ag, down from $24.3 billion in the prior quarter.
• In the past five years, Revenue ranged from a high of $25.4 billion in Q4 2021 to a low of $226.0 million in Q3 2021.
• The 5-year median for Revenue is $12.0 billion (2023), against an average of $9.8 billion.
• Across the five-year window, Revenue jumped 10382.23% in 2021 and plunged 99.0% in 2022, its largest moves.
• Novartis Ag's Revenue stood at $25.4 billion in 2021, then slumped by 99.0% to $254.0 million in 2022, then surged by 8653.94% to $22.2 billion in 2023, then advanced by 9.47% to $24.3 billion in 2024, then tumbled by 42.26% to $14.1 billion in 2025.
• The last three Revenue figures came in at $14.1 billion (Q2 2025), $24.3 billion (Q4 2024), and $12.5 billion (Q2 2024), per Business Quant data.